

PRIOR AUTHORIZATION REQUEST

Dimethyl Fumarate

Patient Information	
Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	
Prescriber Informat	ion
Name:	ion.
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	
Oity, Otato, Zip.	
Requested Medicat	ion
Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of	
Administration:	
Diagnosis and ICD C	ode:
prescribed a medication quantities can be provide Upon receipt of the constitution SECTION A: Please requests. Pharma medications that a	on benefit requires that we review certain requests for coverage with the prescriber. You have for your patient that requires Prior Authorization before benefit coverage or coverage of additional add. Please complete the following questions then fax this form to the toll-free number listed below. In prescription benefit coverage will be determined based on the plan's rules. The prior authorization reviews can be subject to trial with additional are not listed within the criteria. The policies are subject to change based the ements, MDH transmittals and updates to treatment guidelines.
1 Is the reque	st for INITIAL or CONTINUATION of therapy?
[] Initial (If cl	necked, go to 7)
[] Continuati	on (If checked, go to 2)
•	t currently receiving the requested medication? Yes No question 7.]

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

3	Has the patient been receiving medication samples of dimethyl fumarate? [If yes, skip to question 7.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
5	Has the patient been established on therapy for at least 3 months? [If no, skip to question 7.]	Yes	No
6	Has documentation been submitted to confirm that the patient has had a significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [No further questions.]	Yes	No
7	What is the indication or diagnosis? [] Relapsing forms of multiple sclerosis (for example: clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease) (If checked, go to 8)		
	[] Non-relapsing forms of multiple sclerosis (for example: primary progressive multiple sclerosis) (If checked, no further questions)		
	[] Other (If checked, no further questions)		
8	Is the medication being prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis? [If no, no further questions.]	Yes	No
9	Will the patient be using the requested medication in combination with another disease-modifying agent used for multiple sclerosis [MS]? [Note: Examples include Avonex, Rebif, Betaseron, Extavia, Copaxone, Glatopa, Plegridy, Lemtrada, Tysabri, Gilenya, Mavenclad, Mayzent, Aubagio, Ocrevus, Bafiertam, Vumerity, Zeposia, and Kesimpta.]	Yes	No

Please document the diagnoses	symptoms, and/or any other information important to this review:



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 07.2025